Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic

Remi A. Kessler; Maureen A. Mealy; Michael Levy

doi:10.1007/s11940-015-0387-9

Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic

Remi A. Kessler, Maureen A. Mealy, Michael Levy

School of Medicine

Research output: Contribution to journal › Review article › peer-review

73 Scopus citations

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord leading to blindness and paralysis. The spectrum of the disease has expanded based on the specificity of the autoimmune response to the aquaporin-4 water channel on astrocytes. With wider recognition of NMOSD, a standard of care for treatment of this condition has condition based on a growing series of retrospective and prospective studies. This review covers the present state of the field in the treatment of acute relapses, preventive approaches, and therapies for symptoms of NMOSD.

Original language	English (US)
Article number	2
Pages (from-to)	1-15
Number of pages	15
Journal	Current Treatment Options in Neurology
Volume	18
Issue number	1
DOIs	https://doi.org/10.1007/s11940-015-0387-9
State	Published - Jan 1 2016

Keywords

Azathioprine
Eculizumab
Immunosuppression
Mycophenolate
Neuromyelitis optica spectrum disorder
Rituximab

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1007/s11940-015-0387-9

Cite this

@article{cd9c2803509e4782a30ba7ff91fb3d05,

title = "Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic",

abstract = "Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord leading to blindness and paralysis. The spectrum of the disease has expanded based on the specificity of the autoimmune response to the aquaporin-4 water channel on astrocytes. With wider recognition of NMOSD, a standard of care for treatment of this condition has condition based on a growing series of retrospective and prospective studies. This review covers the present state of the field in the treatment of acute relapses, preventive approaches, and therapies for symptoms of NMOSD.",

keywords = "Azathioprine, Eculizumab, Immunosuppression, Mycophenolate, Neuromyelitis optica spectrum disorder, Rituximab",

author = "Kessler, {Remi A.} and Mealy, {Maureen A.} and Michael Levy",

note = "Funding Information: This work was funded by NINDS grant NS078555, PI Levy. Funding Information: Michael Levy receives research support from NIH, Guthy Jackson Charitable Foundation, Viropharma, Acorda, Sanofi, NeuralStem and Genentech, and serves as a consultant for Chugai Pharmaceuticals, GlaxoSmithKline and Medimmune. Publisher Copyright: {\textcopyright} 2015, Springer Science+Business Media New York.",

year = "2016",

month = jan,

day = "1",

doi = "10.1007/s11940-015-0387-9",

language = "English (US)",

volume = "18",

pages = "1--15",

journal = "Current Treatment Options in Neurology",

issn = "1092-8480",

publisher = "Current Science, Inc.",

number = "1",

}

TY - JOUR

T1 - Treatment of Neuromyelitis Optica Spectrum Disorder

T2 - Acute, Preventive, and Symptomatic

AU - Kessler, Remi A.

AU - Mealy, Maureen A.

AU - Levy, Michael

N1 - Funding Information: This work was funded by NINDS grant NS078555, PI Levy. Funding Information: Michael Levy receives research support from NIH, Guthy Jackson Charitable Foundation, Viropharma, Acorda, Sanofi, NeuralStem and Genentech, and serves as a consultant for Chugai Pharmaceuticals, GlaxoSmithKline and Medimmune. Publisher Copyright: © 2015, Springer Science+Business Media New York.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord leading to blindness and paralysis. The spectrum of the disease has expanded based on the specificity of the autoimmune response to the aquaporin-4 water channel on astrocytes. With wider recognition of NMOSD, a standard of care for treatment of this condition has condition based on a growing series of retrospective and prospective studies. This review covers the present state of the field in the treatment of acute relapses, preventive approaches, and therapies for symptoms of NMOSD.

AB - Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord leading to blindness and paralysis. The spectrum of the disease has expanded based on the specificity of the autoimmune response to the aquaporin-4 water channel on astrocytes. With wider recognition of NMOSD, a standard of care for treatment of this condition has condition based on a growing series of retrospective and prospective studies. This review covers the present state of the field in the treatment of acute relapses, preventive approaches, and therapies for symptoms of NMOSD.

KW - Azathioprine

KW - Eculizumab

KW - Immunosuppression

KW - Mycophenolate

KW - Neuromyelitis optica spectrum disorder

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84951812559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951812559&partnerID=8YFLogxK

U2 - 10.1007/s11940-015-0387-9

DO - 10.1007/s11940-015-0387-9

M3 - Review article

C2 - 26705758

AN - SCOPUS:84951812559

SN - 1092-8480

VL - 18

SP - 1

EP - 15

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

IS - 1

M1 - 2

ER -

Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this